Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned an average rating of “Hold” from the sixteen analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $63.75.
RNA has been the subject of a number of research reports. Weiss Ratings upgraded shares of Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. Zacks Research raised shares of Avidity Biosciences to a “hold” rating in a research note on Friday, June 19th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Avidity Biosciences in a research report on Friday, August 14th. Wall Street Zen raised Avidity Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 30th. Finally, Cantor Fitzgerald began coverage on Avidity Biosciences in a research report on Thursday, June 18th. They set an “overweight” rating and a $25.00 price target for the company.
Institutional Trading of Avidity Biosciences
Avidity Biosciences Stock Down 6.4%
Shares of RNA stock opened at $8.95 on Friday. Avidity Biosciences has a fifty-two week low of $8.66 and a fifty-two week high of $16.77. The stock has a market cap of $153.10 million and a P/E ratio of -4.16. The business has a fifty day simple moving average of $12.18 and a 200-day simple moving average of $12.91.
Avidity Biosciences (NASDAQ:RNA – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($1.18) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.24. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $0.67 million. On average, sell-side analysts anticipate that Avidity Biosciences will post -5.08 earnings per share for the current year.
About Avidity Biosciences
Avidity Biosciences, Inc is a biopharmaceutical company focused on developing RNA therapeutics for diseases that have historically been difficult to treat with conventional drug-delivery methods. Founded in 2012 and headquartered in San Diego, California, the company develops medicines intended to address genetic disorders, with an emphasis on diseases affecting muscles.
Avidity’s proprietary Antibody Oligonucleotide Conjugate (AOC) platform combines the targeting capabilities of monoclonal antibodies with the gene-modifying potential of oligonucleotides, including small interfering RNA and antisense oligonucleotides.
Featured Stories
- Five stocks we like better than Avidity Biosciences
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
